Prana gets OK for Alzheimer's drug trial

11/23/2011 | Wall Street Journal, The · MarketWatch

Prana Biotechnology said it got the OK from Australia's Austin Health Research Ethics Committee to move forward with a long-term Phase II trial of PBT2, its experimental drug for mild Alzheimer's disease. Researchers will use PiB-PET imaging to measure the drug's effect on amyloid deposits in patients' brains and F-FDG PET to determine effects on increasing brain activity.

View Full Article in:

Wall Street Journal, The · MarketWatch

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN